Broadfin Capital

Edesa Biotech is a clinical-stage biotechnology company dedicated to developing innovative treatments for dermatological and anorectal diseases, with a primary focus on inflammatory and immune-related conditions. The company aims to create safe and effective alternatives to topical steroids, which can have undesirable side effects. Its lead product candidate, EB01, is a non-steroidal anti-inflammatory treatment specifically designed for chronic allergic contact dermatitis and has shown statistically significant improvements in clinical studies. Additionally, Edesa Biotech is developing EB05, a monoclonal antibody therapy targeting hospitalized COVID-19 patients. The company is engaged in research and development, manufacturing, and the commercialization of its pharmaceutical products.

Heron Therapeutics is a biotechnology company dedicated to developing innovative treatments for unmet medical needs, primarily in the area of nausea and pain management. Utilizing its proprietary Biochronomer drug delivery technology, the company provides sustained therapeutic levels of short-acting pharmacological agents with a single administration over several days. Heron's product offerings include SUSTOL, an extended-release injection designed to prevent nausea and vomiting associated with certain chemotherapy regimens, and CINVANTI, an intravenous formulation for managing nausea linked to highly emetogenic chemotherapy. The company is also advancing investigational products such as HTX-011, a dual-acting combination of bupivacaine and meloxicam currently in Phase III trials for pain management, and HTX-034 for postoperative pain. Founded in 1983 and headquartered in San Diego, California, Heron Therapeutics was previously known as A.P. Pharma, Inc. before rebranding in 2014.

Arch Oncology, Inc. is an immuno-oncology company focused on discovering and developing antibody therapeutics for the treatment of solid tumors and hematologic cancers. Established in 2006 and headquartered in Brisbane, California, with a research laboratory in St. Louis, Missouri, the company specializes in anti-CD47 antibodies that represent a novel class of checkpoint inhibitors. These second-generation antibodies are designed to engage both the adaptive and innate immune systems, effectively targeting and killing tumor cells. By harnessing the body's immune response, Arch Oncology aims to provide new treatment options for patients battling cancer.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for pain management and addiction medicine. Headquartered in Raleigh, North Carolina, the company utilizes its proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology, which features a small erodible polymer film designed for application to the buccal mucosa. Its product offerings include BELBUCA, a buprenorphine buccal film for chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for opioid dependence; ONSOLIS, a fentanyl buccal soluble film for breakthrough cancer pain; and Symproic, which addresses opioid-induced constipation in adult patients with chronic non-cancer pain. Founded in 1997, BioDelivery Sciences is committed to addressing significant unmet medical needs through innovative therapeutic solutions.

STRATA Skin Sciences, Inc. is a medical technology company focused on developing, commercializing, and marketing products for the treatment of dermatologic conditions. Founded in 1989 and based in Horsham, Pennsylvania, the company operates primarily in two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its key products include the XTRAC excimer laser and VTRAC lamp systems, which are used to treat a variety of skin disorders such as psoriasis, vitiligo, atopic dermatitis, and eczema. Additionally, STRATA offers the MelaFind system, designed to aid in the identification and management of melanoma skin cancer. The company distributes its products both domestically, directly to physicians, and internationally through distributors.

Iovance Biotherapeutics is a clinical-stage biotechnology company based in San Carlos, California, specializing in the development and commercialization of cancer immunotherapy products that utilize the immune system to target and eliminate cancer cells. The company's primary focus is on tumor-infiltrating lymphocyte (TIL) therapies, with its lead candidates, lifileucel and LN-145, currently undergoing Phase II clinical trials for metastatic melanoma and metastatic cervical cancer, respectively. Iovance is also exploring additional applications of TIL and peripheral blood lymphocyte therapies for various cancers, including squamous cell carcinoma of the head and neck and chronic lymphocytic leukemia, through sponsored trials and collaborative efforts with notable research institutions. Established in 2007, Iovance aims to become a leader in the innovation and delivery of TIL therapies for solid tumors, actively preparing for potential regulatory approvals and market entry in the United States.

Recro Pharma is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. The company's lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo-controlled trial demonstrating pain relief. It was founded in 2007 and headquartered in Malvern, Pennsylvania.

ContraFect Corporation is a clinical-stage biotechnology firm based in Yonkers, New York, specializing in the development of therapeutic proteins and antibodies for the treatment of life-threatening, drug-resistant infectious diseases. The company's lead candidate, CF-301, is a novel lysin currently undergoing Phase III clinical trials for staphylococcus aureus bacteremia, including endocarditis. ContraFect is also advancing CF-296, an engineered lysin targeting invasive staphylococcal infections, and CF-370, an investigational therapy in preclinical stages aimed at treating infections caused by pseudomonas aeruginosa. The company has a research collaboration with The Rockefeller University to identify novel lysin candidates targeting gram-negative pathogens. Additionally, ContraFect has initiated an expanded access program for exebacase, intended for patients with persistent bacteremia linked to methicillin-resistant Staphylococcus aureus in COVID-19 cases. Founded in 2008, ContraFect aims to address the challenges posed by multi-drug resistant infections through its innovative treatments.

Ardelyx, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative oral therapeutics for cardiorenal diseases. Founded in 2007 and headquartered in Fremont, California, the company focuses on addressing significant unmet medical needs through first-in-class medicines. Its lead product candidate, tenapanor, has completed Phase 3 clinical trials for treating irritable bowel syndrome with constipation and hyperphosphatemia in end-stage renal disease patients on dialysis. Additionally, Ardelyx is advancing RDX013, a small molecule potassium secretagogue targeting hyperkalemia, and has other candidates in its pipeline, including RDX002 and RDX009, which are in preclinical development for chronic kidney disease and type 2 diabetes, respectively. Ardelyx employs a proprietary drug discovery platform aimed at creating non-systemic products that target specific transporters and receptors to minimize side effects associated with systemic exposure.

Aralez Pharmaceuticals is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of products primarily in cardiovascular care, pain management, and other specialized areas. The company offers a range of key products such as Fiorinal, Proferrin, Fibricor, Uracyst, Neovisc, and Cambia. Aralez operates primarily in the United States and Canada, with the majority of its revenue generated from the U.S. market. By serving customers worldwide, Aralez Pharmaceuticals aims to address significant medical needs through its targeted therapeutic offerings.

Advaxis, Inc. is a clinical-stage biotechnology company based in Princeton, New Jersey, focused on developing innovative immunotherapies for cancer and infectious diseases. The company's therapies utilize a novel platform based on bio-engineered, live attenuated bacteria that secrete antigen/adjuvant fusion proteins to harness the immune system's response against cancer. Key products under development include axalimogene filolisbac (AXAL), which is in phase II trials for head and neck cancer, and ADXS-PSA for prostate cancer. Additionally, Advaxis is working on ADXS-NEO, which tailors immunotherapy based on a patient's tumor neoantigens, ADXS-HOT for boosting anti-cancer immunity, and ADXS-HER2, targeting HER2-expressing solid tumors. The company has established collaborations and licensing agreements with several organizations, enhancing its research capabilities and development efforts.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and licensing of small molecules and biologics aimed at treating and preventing human diseases. The company has two primary portfolios: immunology and central nervous system (CNS). The immunology portfolio includes vaccines and biologics designed to combat infectious diseases, immunosuppression, cancer, and autoimmune disorders. Notable vaccine candidates include TNX-1800, a live replicating vaccine for COVID-19, and TNX-801, a vaccine for smallpox and monkeypox. The CNS portfolio features therapies for pain, neurological, psychiatric, and addiction conditions, including TNX-102 SL, which is in Phase 3 for fibromyalgia management. Other candidates in development target cocaine intoxication, depression, and migraine treatment. Additionally, Tonix is advancing several preclinical candidates aimed at conditions such as post-traumatic stress disorder and organ transplant rejection. Founded in 2007 and based in New York, Tonix is committed to alleviating suffering through innovative therapeutic solutions.

Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company’s primary focus is on rare endocrine disorders, exemplified by its product candidates, Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Strongbridge also offers Keveyis, an oral carbonic anhydrase inhibitor approved for treating specific forms of periodic paralysis in the United States. Founded in 1996 and headquartered in Trevose, Pennsylvania, the company aims to leverage a concentrated prescriber base for its products and plans to utilize a targeted sales force for marketing in the U.S., European Union, and other key markets. Additionally, Strongbridge seeks to enhance its portfolio through the in-licensing or acquisition of complementary products that align with its focus on rare endocrine conditions.

RedHill Biopharma Ltd. is a specialty biopharmaceutical company headquartered in Tel Aviv, Israel, with a primary focus on gastrointestinal and infectious diseases. The company develops and promotes several gastrointestinal drugs, including Movantik for opioid-induced constipation, Talicia for treating Helicobacter pylori infection, and Aemcolo for travelers' diarrhea. RedHill's late-stage clinical development programs include RHB-204, aimed at treating pulmonary nontuberculous mycobacteria infections; RHB-104 for Crohn's disease; and RHB-102 (Bekinda), which has shown promise in Phase 3 studies for acute gastroenteritis and gastritis. Additionally, the company is advancing RHB-107, a serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and opaganib, which is being investigated for various conditions, including COVID-19. Founded in 2009, RedHill Biopharma is committed to innovation in the management of gastrointestinal and infectious diseases.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on developing innovative treatments for neuropsychiatric and neurologic diseases, as well as other disorders affecting the central nervous system (CNS) in the United States. The company’s lead drug candidate, CAPLYTA, targets schizophrenia, bipolar disorder, and behavioral disturbances associated with dementia and autism. In addition to CAPLYTA, the company is advancing several other candidates, including ITI-002, which inhibits phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, aimed at substance use disorders and related psychiatric conditions such as depression and anxiety. Intra-Cellular Therapies also utilizes its CNSProfile technology platform to generate molecular signatures for drug compounds, enhancing insights into the actions of CNS drugs and aiding in drug discovery. The company is headquartered in New York, New York.